Witherow revised the full year outlook: "we now expect to deliver full year adjusted EBITDA of $780 million to $805 million." He cited a realistic assessment of business conditions and a focus on ...
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has entered into an exclusive option agreement with Incyte Corporation (Nasdaq: INCY) for its mutant-selective JAK2V617F JH2 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback